Big Pharma’s battle against FDA-approved medicine imports from Canada

Florida's groundbreaking move: Importing affordable medication from Canada. Big Pharma's pushback and the FDA's historic approval — a turning point in U.S. healthcare?


NationofChange remains a vital, ad-free source of progressive news and activism, all thanks to donations from readers like you. Support our transparent, reader-funded journalism with your generous donation.

In a landmark decision, the Food and Drug Administration (FDA) approved Florida’s program to import prescription drugs from Canada, potentially opening the door for significant cost savings. This historic move, however, was met with immediate backlash from the pharmaceutical lobby. Stephen Ubl, CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA), vehemently opposed the decision, branding it “reckless” and vowing to “consider all options” to prevent its implementation.

The FDA’s approval marks a significant shift in the long-standing battle over drug prices in the United States. It sets a precedent that could challenge the traditionally high costs of medications, forcing millions of Americans to often choose between financial stability and essential healthcare.

For decades, activists and politicians like Senator Bernie Sanders have been advocating for the importation of more affordable prescription drugs from Canada. Over twenty years ago, Sanders made headlines by leading a group of women across the U.S.-Canada border to purchase breast cancer medication at lower costs. This event underscored the vast price discrepancies between the two countries and spotlighted the need for more affordable healthcare options in the U.S.

In 2019, Sanders continued this crusade, accompanying a group of Type 1 diabetes patients to Canada to buy insulin, a drug priced exorbitantly higher in the U.S. These efforts have highlighted the dire need for alternative solutions to the U.S.’s escalating drug prices.

With the FDA’s recent approval, Florida is poised to become the first state in the U.S. to import prescription drugs from Canada. The state anticipates saving up to $150 million in the first year alone, targeting medications for HIV, AIDS, diabetes, hepatitis C, and psychiatric conditions. This program is a significant step towards reducing healthcare costs and improving access to essential medicines.

According to the RAND Corporation, the price disparity is stark, with Canadians paying less than half of what Americans do for brand-name drugs. Florida’s program aims to capitalize on these differences, offering residents access to more affordable medication options.

Before the program can officially launch, Florida must fulfill several requirements as set by the FDA. The state is required to provide detailed information on the drugs to be imported, ensuring their authenticity and compliance with the FDA’s stringent standards. Additionally, Florida must adapt the labeling on these drugs to align with FDA-approved labels, a crucial step to ensure consumer safety and regulatory compliance.

The process involves meticulous planning and execution, demonstrating Florida’s commitment to providing safe, cost-effective medication alternatives to its residents.

Following Florida’s lead, several other states, including Maine, Vermont, and Colorado, have passed laws to establish their own drug importation programs. These states are currently awaiting FDA approval to proceed, signaling a growing trend towards adopting more economically feasible healthcare solutions.

FDA Commissioner Robert Califf has expressed the agency’s dedication to collaborating with states on developing successful importation proposals. These proposals must demonstrate significant cost savings for consumers without compromising the safety and effectiveness of the drugs.

The pharmaceutical industry, known for its influential lobbying efforts, is gearing up to challenge the importation programs. Having spent billions on lobbying over the past decade, the industry is notorious for its resistance to government efforts aimed at reducing drug costs. The FDA’s decision has reignited industry fears of losing control over pricing, leading to intensified lobbying efforts to maintain the status quo.

Amidst this battle, patient advocates stress the need for comprehensive, federal-level solutions to address the high cost of drugs. David Mitchell, founder of Patients for Affordable Drugs and a cancer patient, emphasizes that while state-by-state importation is a step forward, it does not provide a nationwide solution. Mitchell, who depends on expensive medications, calls for federal actions that would lower prices across the board, ensuring accessibility and affordability for all Americans.

To authorize State Importation Programs (SIPs), the FDA requires detailed proposals demonstrating that the programs will significantly reduce consumer costs without exposing them to unsafe or ineffective drugs. The authorized Florida program is scheduled for two years, during which the state must meet a host of obligations, including submitting quarterly reports on imported drugs, monitoring adverse events, and adhering to drug recall procedures.

In its commitment to assist states and tribes, the FDA has published a compliance guide and developed tips to aid in the development of SIP proposals. These resources are part of the agency’s broader initiative to collaborate with interested parties in reducing drug costs while maintaining high standards of safety and effectiveness.

The FDA’s decision to approve Florida’s drug importation program represents a potential turning point in U.S. drug policy. It signals a growing recognition of the need for more affordable healthcare options and challenges the long-standing dominance of the pharmaceutical industry in dictating drug prices.

In the words of FDA Commissioner Robert Califf, “This milestone reflects our ongoing commitment to making lifesaving drugs more accessible and affordable for the American public.”


If you liked this article, please donate $5 to keep NationofChange online through November.